Author

Kenji Yamaoka

Observed names: K Yamaoka, KENJI YAMAOKA, Yamaoka, K., 山岡, 賢治

Observed institutions: Hiroshima University, Tsuchiura Kyodo General Hospital, Hiroshima University Hospital, Onomichi General Hospital, Toranomon Hospital, Omori Red Cross Hospital, Research Institute for Radiation Biology and Medicine, Hiroshima University

ORCID: 0000-0002-8896-3455

Observed ORCID: 0000-0002-8896-3455

OpenAlex ID: A5012700840

Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein

2021 · Yumi Kosaka, Tomoki Kimura, et al. · Liver Cancer · 43

Incidence of microsatellite instability‐high hepatocellular carcinoma among Japanese patients and response to pembrolizumab

2020 · Tomokazu Kawaoka, Yuwa Ando, et al. · Hepatology Research · 41

Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib

2020 · Yuwa Ando, Tomokazu Kawaoka, et al. · Oncology · 30

A case with life-threatening secondary sclerosing cholangitis caused by nivolumab

2020 · Yuki Yoshikawa, Michio Imamura, et al. · Clinical Journal of Gastroenterology · 25

Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma

2024 · Ryoichi Miura, Atsushi Ono, et al. · Medicine · 23

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

2023 · Shigeki Yano, Tomokazu Kawaoka, et al. · Cancers · 22

PDF

Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability

2020 · Yuwa Ando, Masami Yamauchi, et al. · Clinical Journal of Gastroenterology · 20

Clinicopathological assessment of steatohepatitic hepatocellular carcinoma

2021 · Kenji Yamaoka, Satoshi Saitoh, et al. · Clinics and Research in Hepatology and Gastroenterology · 17

PDF

Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients

2025 · Shintaro Yamasaki, Takashi Nakahara, et al. · Journal of Gastroenterology · 16

PDF

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

2023 · Takahiro Kinami, Kei Amioka, et al. · Cancers · 15

PDF

Evaluation of cold snare polypectomy for small pedunculated (Ip) polyps with thin stalks: a prospective clinical feasibility study

2021 · Jun Arimoto, Hideyuki Chiba, et al. · Scandinavian Journal of Gastroenterology · 15

Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

2024 · Ryoichi Miura, Atsushi Ono, et al. · Journal of Gastroenterology · 14

PDF

Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors

2020 · Shinsuke Uchikawa, Tomokazu Kawaoka, et al. · Oncology · 14

First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

2024 · Yasutoshi Fujii, Tomokazu Kawaoka, et al. · Oncology · 11

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab

2021 · Shigeki Yano, Tomokazu Kawaoka, et al. · Medicine · 11

Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma

2025 · NORIKAZU TANABE, ISSEI SAEKI, et al. · Anticancer Research · 10

Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes

2023 · Yutaro Ogawa, Takashi Nakahara, et al. · European Journal of Gastroenterology & Hepatology · 10

The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment

2022 · Kenji Yamaoka, Kenichiro Kodama, et al. · PLoS ONE · 10

PDF

Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma

2020 · Kenji Yamaoka, Kenichiro Kodama, et al. · Journal of Gastroenterology and Hepatology · 10

Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab

2023 · Chihiro Kikugawa, Shinsuke Uchikawa, et al. · Oncology · 8

Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions

2023 · Shigeki Yano, Tomoki Kimura, et al. · Cancers · 7

PDF

The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib

2023 · Kikugawa Chihiro, Tomokazu Kawaoka, et al. · Oncology · 7

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study

2025 · Ko Hashimoto, Tomokazu Kawaoka, et al. · Liver Cancer · 6

PDF

A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk

2020 · Yumi Kosaka, Tomokazu Kawaoka, et al. · Clinical Journal of Gastroenterology · 6

Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model

2024 · Hikaru Nakahara, Atsushi Ono, et al. · JCO Clinical Cancer Informatics · 5

Works count: 42

Citation count: 417

H-index: 13

I10-index: 19